Clinical Scorecard: Utilizing Machine Learning to Assess the Impact of Systemic Inflammation Response Index on Cardiovascular Disease Risk in Gout: A Retrospective Analysis and Clinical Validation

At a Glance

Key Highlights

• Gout is characterized by elevated uric acid and chronic inflammation, contributing to increased cardiovascular disease risk.
• Systemic inflammation response index (SIRI), derived from neutrophil, monocyte, and lymphocyte counts, effectively reflects systemic inflammation and organ impairment.
• Machine learning models using NHANES data demonstrate the association between SIRI levels and cardiovascular disease risk in gout patients.

Guideline-Based Recommendations

Diagnosis

• Diagnose gout based on patient history and 2015 ACR/EULAR classification criteria.
• Identify cardiovascular disease via patient-reported medical history including congestive heart failure, coronary heart disease, angina, myocardial infarction, and stroke.
• Calculate SIRI using complete blood count parameters: SIRI = (neutrophil count × monocyte count) / lymphocyte count.

Management

• Monitor and manage hyperuricemia and chronic inflammation to reduce cardiovascular risk in gout patients.
• Incorporate SIRI as a complementary biomarker to assess systemic inflammation and cardiovascular risk.
• Use Framingham Risk Score to estimate overall cardiovascular disease risk considering age, cholesterol, HDL, blood pressure, smoking, hypertension, and diabetes.

Monitoring & Follow-up

• Regularly assess blood uric acid levels and complete blood counts to calculate SIRI.
• Monitor cardiovascular symptoms and risk factors including hypertension, diabetes, and metabolic disorders.
• Utilize machine learning-based risk models to identify high-risk gout patients for targeted interventions.

Risks

• Gout patients have more than double the cardiovascular mortality compared to the general population.
• Persistent hyperuricemia and systemic inflammation increase risk of hypertension, heart failure, myocardial infarction, and stroke.
• Suboptimal gout management contributes to elevated cardiovascular morbidity and mortality.

Patient & Prescribing Data

Gout patients aged 20 years and older with available CBC and cardiovascular history data

Incorporation of SIRI into clinical evaluation may improve identification of gout patients at high cardiovascular risk, enabling personalized management strategies.

Clinical Best Practices

• Use standardized questionnaires and medical history to accurately identify gout and cardiovascular disease status.
• Calculate and interpret SIRI as a marker of systemic inflammation in gout patients.
• Apply validated cardiovascular risk models such as the Framingham Risk Score alongside inflammatory markers for comprehensive risk assessment.
• Employ machine learning tools to enhance prediction and stratification of cardiovascular risk in gout populations.
• Ensure multidisciplinary management addressing hyperuricemia, inflammation, and cardiovascular comorbidities.

References

• 2015 ACR/EULAR Classification Criteria for Gout
• Framingham Heart Study Risk Functions
• NHANES Study Overview